BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 4, 2020
Management Tracks

Giroir stepping down as COVID-19 testing czar; plus Gilead, Sanofi Ventures, Varian, Sirtex and Oxford BioMedica

Brett Giroir, who was appointed in March to coordinate the U.S.’s COVID-19 testing efforts, will be “demobilized” from his post mid-June and return to his previous position as assistant secretary for health and head of...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

A Mass General program using gene therapy vectors to develop a COVID-19 vaccine has teed up the multilayered manufacturing capacity needed to get its AAV candidate into the clinic next half, highlighting the front-and-center role...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

Inovio looks to be the second company after Moderna to start a U.S. trial of a COVID-19 vaccine, kicking the study off several months ahead of its previously projected summer trial start date. Outside of...
BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

Genentech identifies blood as source of antitumor T cells   In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T...
BioCentury | Feb 28, 2020
Finance

Passage prices upsized IPO despite market headwinds

The ability of Passage Bio to price its IPO above expectations late Thursday signaled that even with a global pandemic roiling markets, a new biotech listing can still pique investors’ interest. Gene therapy company Passage...
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens than CAR therapies engineered with peripheral blood T cells. The...
BioCentury | Feb 24, 2020
Distillery Therapeutics

TRIM25 identified as liver cancer target

DISEASE CATEGORY: Cancer INDICATION: Liver cancer Blocking TRIM25, an endoplasmic reticulum stress response protein, could treat hepatocellular carcinoma (HCC). High tumor levels of TRIM25 protein were associated with poor overall survival, disease-free survival and progression-free...
Items per page:
1 - 10 of 810
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 4, 2020
Management Tracks

Giroir stepping down as COVID-19 testing czar; plus Gilead, Sanofi Ventures, Varian, Sirtex and Oxford BioMedica

Brett Giroir, who was appointed in March to coordinate the U.S.’s COVID-19 testing efforts, will be “demobilized” from his post mid-June and return to his previous position as assistant secretary for health and head of...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

A Mass General program using gene therapy vectors to develop a COVID-19 vaccine has teed up the multilayered manufacturing capacity needed to get its AAV candidate into the clinic next half, highlighting the front-and-center role...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

Inovio looks to be the second company after Moderna to start a U.S. trial of a COVID-19 vaccine, kicking the study off several months ahead of its previously projected summer trial start date. Outside of...
BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

Genentech identifies blood as source of antitumor T cells   In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T...
BioCentury | Feb 28, 2020
Finance

Passage prices upsized IPO despite market headwinds

The ability of Passage Bio to price its IPO above expectations late Thursday signaled that even with a global pandemic roiling markets, a new biotech listing can still pique investors’ interest. Gene therapy company Passage...
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens than CAR therapies engineered with peripheral blood T cells. The...
BioCentury | Feb 24, 2020
Distillery Therapeutics

TRIM25 identified as liver cancer target

DISEASE CATEGORY: Cancer INDICATION: Liver cancer Blocking TRIM25, an endoplasmic reticulum stress response protein, could treat hepatocellular carcinoma (HCC). High tumor levels of TRIM25 protein were associated with poor overall survival, disease-free survival and progression-free...
Items per page:
1 - 10 of 810